00
000403.SHE Pacific Shuanglin Bio pharmacy Co Ltd
- Market cap
- CNY 9.07B
- P/E
- 43.4x
- P/B
- 1.12x
- ROE
- 2.5%
- Dividend yield
- 3.02%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000403.SHE undervalued?
Graham number000403.SHE trades 47.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pacific Shuanglin Bio pharmacy Co Ltd fundamental analysis
No fundamental analysis for Pacific Shuanglin Bio pharmacy Co Ltd yet.
Pacific Shuanglin Bio pharmacy Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pacific Shuanglin Bio pharmacy Co Ltd
Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen, lyophilized intravenous immunoglobulin (pH4), hepatitis B immunoglobulin (pH4)…
Full company profilePacific Shuanglin Bio pharmacy Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pacific Shuanglin Bio pharmacy Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 561M | 685M | 860M | 916M | 1.05B | 1.97B | 2.41B | 2.33B | 2.65B | 2.63B | 1.87B |
| Gross Profit | 314M | 390M | 459M | 477M | 513M | 908M | 1.25B | 1.20B | 1.30B | 1.09B | 602M |
| Operating Income | 59.6M | 83.6M | 93.5M | 180M | 220M | 460M | 663M | 695M | 880M | 587M | 206M |
| EBITDA | 128M | 158M | 167M | 237M | 274M | 538M | 705M | 771M | 914M | 661M | 255M |
| Net Income | 50.1M | 21.6M | 80.0M | 160M | 186M | 391M | 587M | 612M | 745M | 419M | 200M |
| EPS | 0.09 | 0.04 | 0.15 | 0.33 | 0.38 | 0.55 | 0.80 | 0.84 | 1.02 | 0.44 | 0.21 |
| Balance Sheet | |||||||||||
| Total Assets | 1.24B | 1.32B | 1.32B | 1.27B | 1.65B | 7.09B | 7.98B | 8.63B | 9.25B | 9.47B | 9.66B |
| Total Liabilities | 696M | 762M | 698M | 470M | 686M | 760M | 1.12B | 1.21B | 1.33B | 1.39B | 1.71B |
| Shareholders' Equity | 554M | 572M | 638M | 800M | 965M | 6.33B | 6.87B | 7.43B | 7.92B | 8.09B | 7.96B |
| Cash & Short-term Investments | 203M | 146M | 155M | 111M | 103M | 1.12B | 1.42B | 1.85B | 1.60B | 770M | 531M |
| Total Debt | 247M | 224M | 180M | 110M | 352M | 141M | 373M | 468M | 632M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 62.5M | -35.9M | 117M | 191M | 195M | 408M | 524M | 679M | 322M | -216M | - |
| Capital Expenditure | 98.0M | 39.9M | 35.0M | 41.1M | 40.2M | 326M | 379M | 377M | 521M | 333M | 191M |
| Free Cash Flow | -35.5M | -75.8M | 81.6M | 150M | 155M | 82.1M | 146M | 302M | -199M | -549M | -36.4M |
| Ratios | |||||||||||
| ROE | 9.0% | 3.8% | 12.5% | 20.1% | 19.3% | 6.2% | 8.5% | 8.2% | 9.4% | 5.2% | 2.5% |
| ROA | 4.0% | 1.6% | 6.1% | 12.6% | 11.3% | 5.5% | 7.4% | 7.1% | 8.1% | 4.4% | 2.1% |
| Net Profit Margin | 8.9% | 3.2% | 9.3% | 17.5% | 17.7% | 19.8% | 24.4% | 26.3% | 28.1% | 15.9% | 10.7% |
| Debt to Equity | 0.45x | 0.39x | 0.28x | 0.14x | 0.37x | 0.02x | 0.05x | 0.06x | 0.08x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pacific Shuanglin Bio pharmacy Co Ltd dividends
- Dividend yield
- 3.02%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 65.3%
- Ex-dividend date
- Oct 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 274M | 0.29 | 65.3% |
| 2024 | CNY 265M | 0.36 | 35.5% |
| 2023 | CNY 58.6M | 0.08 | 9.6% |
| 2022 | CNY 41.0M | 0.06 | 7.0% |
| 2021 | CNY 141K | 0.00 | 0.0% |
| 2020 | CNY 32.8M | 0.07 | 17.7% |
| 2019 | CNY 145M | 0.30 | 90.1% |
| 2018 | CNY 23.3M | 0.04 | 29.1% |
| 2017 | CNY 5.01M | 0.01 | 23.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on Jun 4, 2025.
Who owns Pacific Shuanglin Bio pharmacy Co Ltd
- Insiders 44.50%
- Institutions 5.11%
- Public & others 50.39%
- Shares outstanding 950M
- Free float 525M
Pacific Shuanglin Bio pharmacy Co Ltd company profile
- Company name
- Pacific Shuanglin Bio pharmacy Co Ltd
- Ticker
- 000403.SHE
- ISIN
- CNE000000F14
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jun 7, 1996
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,755
- Fiscal year end
- December
- Address
- Sunshine City Global Financial Center, Taiyuan, China, 030000
- Phone
- 86 75 9293 1218
- Website
- slbiop.com
About Pacific Shuanglin Bio pharmacy Co Ltd
Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen, lyophilized intravenous immunoglobulin (pH4), hepatitis B immunoglobulin (pH4), and human prothrombin complex concentrate, as well as intravenous cytomegalovirus immunoglobulin and intravenous respiratory syncytial virus immunoglobulin. It is also involved in blood acquisition; plasma collection; consulting; trading; investment activities; and technology promotion and application services. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. was founded in 1993 and is headquartered in Taiyuan, China.
Pacific Shuanglin Bio pharmacy Co Ltd management
8- Mr. Xiankui RongGeneral Manager · born 1974
- Ms. Yehong WangCFO, Head of Accounting Department & Accounting Supervisor · born 1991
- Mr. Lei YanDeputy GM & Director · born 1991
- Mr. Wenbin SiDeputy GM & Non-Independent Director · born 1981
- Ms. Xiaoying HuangDeputy GM & Non-Independent Director · born 1974
- Ms. Lan YeDeputy GM & Non-Independent Director · born 1979
- Mr. Yulin ZhaoBoard Secretary · born 1987
- Mr. Qunge ZhangDeputy General Manager · born 1970